JITC

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
Paolo A Ascierto, Dirk Schadendorf

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005082; DOI: 10.1136/jitc-2022-005082
SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response
Kranthi Kiran Kishore Tanagala, Joshua Morin-Baxter, Richard Carvajal, Maryum Cheema, Sunil Dubey, Hiroshi Nakagawa, Angela Yoon, Yi-Shing L Cheng, Alison Taylor, Jeffrey Nickerson, Akiva Mintz, Fatemeh Momen-Heravi

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005088; DOI: 10.1136/jitc-2022-005088
Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor
Takahiro Arai, Tomomi Kokubo, Ruiheng Tang, Hirohito Abo, Ayu Terui, Jotaro Hirakawa, Hidetaka Akita, Hiroto Kawashima, Akihiro Hisaka, Hiroto Hatakeyama

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005657; DOI: 10.1136/jitc-2022-005657
T cells of colorectal cancer patients’ stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells
Sandra Schwarz, Johanna Schmitz, Markus W Löffler, Michael Ghosh, Hans-Georg Rammensee, Evgenia Olshvang, Marvin Markel, Nadine Mockel-Tenbrinck, Andrzej Dzionek, Susann Krake, Basak Arslan, Kapil Dev Kampe, Anne Wendt, Peter Bauer, Christina S Mullins, Andreas Schlosser, Michael Linnebacher

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005651; DOI: 10.1136/jitc-2022-005651
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod Sarnaik

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005755; DOI: 10.1136/jitc-2022-005755
TIGIT blockade repolarizes AML-associated TIGIT⁺ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
Franziska Brauneck, Brit Fischer, Marius Witt, Jana Muschhammer, Jennyfer Oelrich, Pedro Henrique da Costa Avelar, Sophia Tsoka, Lars Bullinger, Elisa Seubert, Daniel J Smit, Carsten Bokemeyer, Christin Ackermann, Jasmin Wellbrock, Friedrich Haag, Walter Fiedler

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e004794; DOI: 10.1136/jitc-2022-004794
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Zhijun Dai, Kongming Wu

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005543; DOI: 10.1136/jitc-2022-005543
Dose–response correlation for CAR-T cells: a systematic review of clinical studies
Anand Rotte, Matthew J Frigault, Ayub Ansari, Brad Gliner, Christopher Heery, Bijal Shah

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005678; DOI: 10.1136/jitc-2022-005678
In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade
Chenkai Mao, Veronique Beiss, Gregory W Ho, Jennifer Fields, Nicole F Steinmetz, Steven Fiering

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005834; DOI: 10.1136/jitc-2022-005834
Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
Fabiana Pani, Yoshinori Yasuda, Sylvie T Rousseau, Kevin C Bermea, Solmaz Roshanmehr, Rulin Wang, Srinivasan Yegnasubramanian, Patrizio Caturegli, Luigi Adamo

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005538; DOI: 10.1136/jitc-2022-005538

Main menu

JITC

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

JITC

Pages